1. Home
  2. INBK vs IKT Comparison

INBK vs IKT Comparison

Compare INBK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Internet Bancorp

INBK

First Internet Bancorp

HOLD

Current Price

$26.52

Market Cap

226.9M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.04

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBK
IKT
Founded
1999
2008
Country
United States
United States
Employees
355
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.9M
220.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
INBK
IKT
Price
$26.52
$2.04
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$23.25
$5.00
AVG Volume (30 Days)
31.1K
887.2K
Earning Date
04-30-2026
03-26-2026
Dividend Yield
1.06%
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$279.34
N/A
Revenue Next Year
$12.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.05
$1.33
52 Week High
$28.88
$2.26

Technical Indicators

Market Signals
Indicator
INBK
IKT
Relative Strength Index (RSI) 50.18 66.00
Support Level $24.92 $1.59
Resistance Level $26.47 $2.13
Average True Range (ATR) 1.01 0.11
MACD -0.19 0.02
Stochastic Oscillator 25.81 73.53

Price Performance

Historical Comparison
INBK
IKT

About INBK First Internet Bancorp

First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: